Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with diagnosis of idiopathic Parkinson's Disease (PD) that is levodopa-responsive~* Participants must be judged by the investigator to be inadequately controlled by current therapy, have recognizable/identifiable Off and On states (motor fluctuations), and have a minimum of 2.5 hours of Off time per day~Exclusion Criteria:~* Participant is cognitively impaired and is not able to safely and effectively manage the drug delivery system and the diaries and is not able to adhere to the study~* Participant is considered by the investigator to be an unsuitable candidate to receive ABBV-951 for any reason

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABBV-951 Low Dose Subgroup (Type: EXPERIMENTAL): After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was \< 2530 mg of Foslevodopa/day were analyzed as the Low Dose Subgroup.
- ABBV-951 High Dose Subgroup (Type: EXPERIMENTAL): After a 4-week Optimization Period, participants continued receiving ABBV-951 by continuous subcutaneous infusion (CSCI) during the 48-week Maintenance Period. Participants whose modal total daily dose (most frequent dose) over the entire study was ≥ 2530 mg of Foslevodopa/day were analyzed as the High Dose Subgroup.

Based on this trial design, predict the completion outcome and termination type (if applicable).